Strategic Acquisition SDL was acquired by StatLab Medical Products in 2024, expanding StatLab’s manufacturing competencies to include microbiology and strengthening end-to-end histology workflow capabilities. This creates cross-sell opportunities to StatLab customers and expands service offerings for pathology labs.

Expanded Capabilities The combination of TB testing solutions, microbiology stains, and control slides positions the company to address end-to-end lab needs. Focus sales on labs seeking integrated supply chains and standardized histology workflows, leveraging SDL’s and StatLab’s combined portfolio.

Growth Levers Recent product launches and expansions, including CytoPath Disc and pathology slide printer, point to a strategy of expanding manufacturing and product breadth. Target opportunities in labs upgrading workflow efficiency and standardized sample processing.

Sustainability & Recognition SDL and StatLab have earned sustainability accolades via Scientists’ Choice Awards, signaling a market-friendly emphasis on responsible suppliers. Use as a differentiator when engaging procurement teams prioritizing sustainable sourcing and supplier partnerships.

Domestic Expansion The callouts of manufacturing expansion in Arlington, Texas indicate a push toward domestic production and supply chain resilience. Sales can position SDL/StatLab offerings as reliable, locally supported solutions with improved lead times for U.S. labs.